The Story. Since the U.S. Food and Drug Administration (FDA) approved Ferric Citrate on September 5, 2014 Keryx Biopharmaceuticals' (NASDAQ: KERX) share price lost roughly 28 percent. Wall Street analysts seem concerned regarding the drug's label warning of iron overload: "Monitor ferritin and TSAT. Patients may require a reduction in dose or discontinuation of IV iron."

Source: Keryx

Starting at an oral dose of 2 tablets of 210 mg equivalent of ferric iron, Ferric Citrate is prescribed three times a day to patients afflicted by chronic kidney diseases who are currently on dialysis. Depending on the clinical status, as well as, ferritin and transferrin (TSAT) level, clinicians can increase or decrease the dose via adjusting one to two tablets, as needed to treat excess blood phosphate or hyperphosphatemia.

Read more on this report at Retail Investor 360.